Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics.

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

Analysts have recently evaluated Elanco Animal Health and provided 12-month price targets. The average target is $15.25, ...

Guidelines aimed at increasing transparency about how the regulator will evaluate pharmaceutical pricing, official says ...

The real-world evidence solutions market is largely driven by the increasing prevalence of chronic diseases and their impact on real-world healthcare ...